In this mini review, we describe recent developments in treatment approaches that incorporate antibodies in the therapeutic context of MDS apart from immune checkpoint inhibitors.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Myelodysplastic syndromes (MDS) encompass a heterogeneous set of myeloid neoplasms characterized by ineffective hematopoiesis.
📊
Key Findings & Data:Hypomethylating agents have remained the standard of care for higher-risk MDS for almost 2 decades.
💡
Conclusion & Impact:In this mini review, we describe recent developments in treatment approaches that incorporate antibodies in the therapeutic context of MDS apart from immune checkpoint inhibitors.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Myelodysplastic syndromes (MDS) encompass a heterogeneous set of myeloid neoplasms characterized by ineffective hematopoiesis. Treatment remains challenging, especially for patients with unfavorable disease features. Hypomethylating agents have remained the standard of care for higher-risk MDS for almost 2 decades. A plethora of clinical trials utilizing different approaches ranging from small molecule inhibitors to antibodies are underway. In this mini review, we describe recent developments in treatment approaches that incorporate antibodies in the therapeutic context of MDS apart from immune checkpoint inhibitors.
🔖
Cite This Article
DEEB, G., PAPADANATONAKİS, N. (2022). Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments. Erciyes Medical Journal, Cilt: 44 - Sayı: 3, 245–251. https://ajindex.com/articles/502158
Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep 2015; 10(3): 272–81
Jonas BA, Greenberg PL. MDS prognostic scoring systems – past, present, and future. Best Pract Res Clin Haematol 2015; 28(1): 3–13
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10(3): 223–32
Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J 2018; 8(6): 55
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106(8): 1794–803
Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia- Manero G, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27(23): 3842–8
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 2016; 30(2): 268–73
Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, et al. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011; 117(6): 1253–61. 9. de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, et al. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Ann Hematol 2015; 94(12): 1981–9
Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, et al. Role of CD47 in Hematological Malignancies. J Hematol Oncol 2020; 13(1): 96
Bian Z, Shi L, Guo YL, Lv Z, Tang C, Niu S, et al. Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagoc